Literature DB >> 28161391

Spinal muscular atrophy: Factors that modulate motor neurone vulnerability.

Wen-Yo Tu1, Julie E Simpson1, J Robin Highley1, Paul R Heath2.   

Abstract

Spinal muscular atrophy (SMA), a leading genetic cause of infant death, is a neurodegenerative disease characterised by the selective loss of particular groups of motor neurones in the anterior horn of the spinal cord with concomitant muscle weakness. To date, no effective treatment is available, however, there are ongoing clinical trials are in place which promise much for the future. However, there remains an ongoing problem in trying to link a single gene loss to motor neurone degeneration. Fortunately, given successful disease models that have been established and intensive studies on SMN functions in the past ten years, we are fast approaching the stage of identifying the underlying mechanisms of SMA pathogenesis Here we discuss potential disease modifying factors on motor neurone vulnerability, in the belief that these factors give insight into the pathological mechanisms of SMA and therefore possible therapeutic targets.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease modifier; Motor neurone disease; SMA; SMN; Selective vulnerability

Mesh:

Year:  2017        PMID: 28161391     DOI: 10.1016/j.nbd.2017.01.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  9 in total

Review 1.  Treatment Advances in Spinal Muscular Atrophy.

Authors:  Diana Bharucha-Goebel; Petra Kaufmann
Journal:  Curr Neurol Neurosci Rep       Date:  2017-10-06       Impact factor: 5.081

Review 2.  UsnRNP biogenesis: mechanisms and regulation.

Authors:  Oliver J Gruss; Rajyalakshmi Meduri; Maximilian Schilling; Utz Fischer
Journal:  Chromosoma       Date:  2017-08-01       Impact factor: 4.316

Review 3.  Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2017-12-07       Impact factor: 5.639

Review 4.  RNA-binding proteins in neurodegeneration: mechanisms in aggregate.

Authors:  Erin G Conlon; James L Manley
Journal:  Genes Dev       Date:  2017-08-01       Impact factor: 11.361

Review 5.  Multifaceted roles of microRNAs: From motor neuron generation in embryos to degeneration in spinal muscular atrophy.

Authors:  Tai-Heng Chen; Jun-An Chen
Journal:  Elife       Date:  2019-11-18       Impact factor: 8.140

Review 6.  Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy.

Authors:  Yang-Jean Li; Tai-Heng Chen; Yan-Zhang Wu; Yung-Hao Tseng
Journal:  Nutrients       Date:  2020-12-16       Impact factor: 5.717

Review 7.  Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy.

Authors:  Tai-Heng Chen
Journal:  Ther Adv Neurol Disord       Date:  2020-12-25       Impact factor: 6.570

8.  Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism.

Authors:  Erin G Conlon; Delphine Fagegaltier; Phaedra Agius; Julia Davis-Porada; James Gregory; Isabel Hubbard; Kristy Kang; Duyang Kim; Hemali Phatnani; Justin Kwan; Dhruv Sareen; James R Broach; Zachary Simmons; Ximena Arcila-Londono; Edward B Lee; Vivianna M Van Deerlin; Neil A Shneider; Ernest Fraenkel; Lyle W Ostrow; Frank Baas; Noah Zaitlen; James D Berry; Andrea Malaspina; Pietro Fratta; Gregory A Cox; Leslie M Thompson; Steve Finkbeiner; Efthimios Dardiotis; Timothy M Miller; Siddharthan Chandran; Suvankar Pal; Eran Hornstein; Daniel J MacGowan; Terry Heiman-Patterson; Molly G Hammell; Nikolaos A Patsopoulos; Joshua Dubnau; Avindra Nath; Hemali Phatnani; Neil A Shneider; James L Manley
Journal:  Elife       Date:  2018-07-13       Impact factor: 8.140

Review 9.  New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?

Authors:  Tai-Heng Chen
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.